McTavish D, Heel R C
Adis International Limited, Auckland, New Zealand.
Drugs. 1992 May;43(5):713-33. doi: 10.2165/00003495-199243050-00007.
Dexfenfluramine stimulates serotoninergic activity by inhibiting serotonin reuptake into presynaptic neurons and by enhancing its release into brain synapses. Based on the serotonin hypothesis of appetite control these effects would be expected to reduce food intake and thus body-weight. Studies in animal models and severely overweight patients have confirmed the effectiveness of dexfenfluramine as a weight-reducing agent which appears to be well tolerated. Permanent weight loss is the goal of weight-reducing strategies and, based on current clinical evidence, dexfenfluramine appears to exert a weight reducing effect over periods of up to 12 months without development of tolerance, a problem that has limited the long term use of other pharmacological agents used in the treatment of this disorder. Dexfenfluramine facilitated weight loss in patients who had not responded satisfactorily to other weight-reducing strategies, prevented relapse in those patients who had achieved weight reduction by other methods, and corrected disturbed eating patterns (and therefore reduced weight gain) in small studies involving patients with premenstrual syndrome, seasonal affective disorder and nicotine withdrawal syndrome. Follow-up of the longest study reported with dexfenfluramine suggests that continued therapy is required in severely overweight patients if weight loss is to be maintained. Dexfenfluramine has not been directly compared with nonpharmacological measures of weight control such as behaviour modification or exercise programmes. The decision that pharmacological means are indicated in overweight patients must be highly individualised, and must consider the many complex factors that often contribute to overweight states, as well as the anticipated magnitude of drug effect. Despite such a cautionary note, and the expected need (at this stage of its development) for an expanded clinical study programme in certain areas, dexfenfluramine is a clear advance in the pharmacological approach to improved management of overweight individuals.
右芬氟拉明通过抑制5-羟色胺再摄取进入突触前神经元以及增强其向脑突触的释放来刺激5-羟色胺能活性。基于食欲控制的5-羟色胺假说,预计这些作用会减少食物摄入,从而减轻体重。在动物模型和严重超重患者中进行的研究已证实右芬氟拉明作为一种减肥药物的有效性,而且它似乎耐受性良好。永久性体重减轻是减肥策略的目标,根据目前的临床证据,右芬氟拉明在长达12个月的时间里似乎都能发挥减肥作用,且不会产生耐受性,而耐受性问题限制了用于治疗该疾病的其他药物的长期使用。右芬氟拉明能使对其他减肥策略反应不佳的患者体重减轻,防止那些通过其他方法实现体重减轻的患者体重反弹,并且在涉及经前综合征、季节性情感障碍和尼古丁戒断综合征患者的小型研究中纠正紊乱的饮食模式(从而减少体重增加)。关于右芬氟拉明的最长研究报告的随访表明,如果要维持体重减轻,严重超重患者需要持续治疗。右芬氟拉明尚未与行为矫正或运动计划等非药物体重控制措施进行直接比较。对于超重患者是否应采用药物治疗的决定必须高度个体化,必须考虑到许多常常导致超重状态的复杂因素,以及预期的药物效果大小。尽管有这样的警示,并且在其研发的现阶段预计在某些领域需要扩大临床研究项目,但右芬氟拉明在改善超重个体管理的药理学方法上显然是一个进步。